Propel Bio Management, LLC
13F Reported Value
ⓘ$191.1M
Holdings
29
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Propel Bio Management, LLC disclosed 29 positions worth $191.1M in its Form 13F-HR for Q2 2026, led by $PAGP (PLAINS GP HOLDINGS LP) at 16.2% of the equity portfolio, followed by $ACHV and $CORT. During the quarter the fund opened 3 new positions and exited 12 — including a new stake in $SCYX and a full exit from $VOR. The portfolio is most concentrated in Healthcare (82.4% of disclosed assets). All figures are sourced directly from Propel Bio Management, LLC’s Form 13F-HR filing with the SEC under CIK 1969764.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 55.1#1,269
Quality
$30.9M1,272,360 sh - —
Quality
$26.3M4,034,018 sh - 57.8#1,071
Quality
$11.9M136,499 sh - 40.9
Quality
$11.4M1,050,358 sh - 54.7
Quality
$11.0M871,460 sh - —
Quality
$10.0M7,429,590 sh - —
Quality
$8.1M573,086 sh - —
Quality
$7.9M883,198 sh - 9.7
Quality
$6.8M696,436 sh - 23.7
Quality
$6.1M983,070 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 PLAINS GP HOLDINGS LP$PAGP | 55.1#1,269 | $30.9M | 1,272,360 |
 ACHIEVE LIFE SCIENCES, INC.$ACHV | — | $26.3M | 4,034,018 |
 CORCEPT THERAPEUTICS INC$CORT | 57.8#1,071 | $11.9M | 136,499 |
 Phathom Pharmaceuticals, Inc.$PHAT | 40.9 | $11.4M | 1,050,358 |
 DELCATH SYSTEMS, INC.$DCTH | 54.7 | $11.0M | 871,460 |
 Milestone Pharmaceuticals Inc.$MIST | — | $10.0M | 7,429,590 |
 COMPASS Pathways plc$CMPS | — | $8.1M | 573,086 |
 Kyverna Therapeutics, Inc.$KYTX | — | $7.9M | 883,198 |
 Artiva Biotherapeutics, Inc.$ARTV | 9.7 | $6.8M | 696,436 |
 ABEONA THERAPEUTICS INC.$ABEO | 23.7 | $6.1M | 983,070 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Propel Bio Management, LLC's 29 positions.
Showing top 10 of 29 holdings.
Sector Allocation
Healthcare
$157.5M
Energy
$30.9M
Technology
$2.7M
Full Holdings — Propel Bio Management, LLC (Q2 2026)
All 29 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $PAGP | PLAINS GP HOLDINGS LP | $30.9M | 16.2% | +0% | 55.1 |
| 2 | $ACHV | ACHIEVE LIFE SCIENCES, INC. | $26.3M | 13.8% | +7% | — |
| 3 | $CORT | CORCEPT THERAPEUTICS INC | $11.9M | 6.2% | -8% | 57.8 |
| 4 | $PHAT | Phathom Pharmaceuticals, Inc. | $11.4M | 6.0% | +25% | 40.9 |
| 5 | $DCTH | DELCATH SYSTEMS, INC. | $11.0M | 5.7% | -11% | 54.7 |
| 6 | $MIST | Milestone Pharmaceuticals Inc. | $10.0M | 5.2% | +80% | — |
| 7 | $CMPS | COMPASS Pathways plc | $8.1M | 4.2% | -23% | — |
| 8 | $KYTX | Kyverna Therapeutics, Inc. | $7.9M | 4.1% | +37% | — |
| 9 | $ARTV | Artiva Biotherapeutics, Inc. | $6.8M | 3.5% | +376% | 9.7 |
| 10 | $ABEO | ABEONA THERAPEUTICS INC. | $6.1M | 3.2% | -26% | 23.7 |
| 11 |  $AQST | Aquestive Therapeutics, Inc. | $6.0M | 3.1% | +103% | 14.5 |
| 12 |  $PALI | PALISADE BIO, INC. | $5.4M | 2.8% | +132% | — |
| 13 |  $IMUX | IMMUNIC, INC. | $5.0M | 2.6% | -86% | — |
| 14 |  $IVA | Inventiva S.A. | $4.8M | 2.5% | +77% | — |
| 15 |  $SABS | SAB Biotherapeutics, Inc. | $4.2M | 2.2% | +6% | — |
| 16 |  $OBIO | Orchestra BioMed Holdings, Inc. | $3.9M | 2.0% | +0% | 32 |
| 17 |  $CLDX | Celldex Therapeutics, Inc. | $3.9M | 2.0% | -21% | 8.4 |
| 18 |  $ZVRA | ZEVRA THERAPEUTICS, INC. | $3.6M | 1.9% | -10% | 72.8 |
| 19 |  $OCUL | OCULAR THERAPEUTIX, INC | $3.5M | 1.8% | -6% | 8.4 |
| 20 |  $FDMT | 4D Molecular Therapeutics, Inc. | $3.4M | 1.8% | -34% | 34.5 |
| 21 |  $OVID | Ovid Therapeutics Inc. | $3.0M | 1.6% | +21% | 26.4 |
| 22 |  $EYPT | EyePoint, Inc. | $2.7M | 1.4% | -11% | 3.5 |
| 23 |  $UPB | Upstream Bio, Inc. | $2.4M | 1.3% | +3% | 19.7 |
| 24 |  $SCYX | SCYNEXIS INC | $2.2M | 1.2% | NEW | — |
| 25 |  $SLN | Silence Therapeutics plc | $2.1M | 1.1% | NEW | — |
| 26 |  $LONA | LeonaBio, Inc. | $1.4M | 0.7% | +0% | — |
| 27 |  $MAZE | Maze Therapeutics, Inc. | $1.3M | 0.7% | +0% | 10.3 |
| 28 |  $CRVS | Corvus Pharmaceuticals, Inc. | $1.1M | 0.6% | -18% | — |
| 29 |  $SGMT | Sagimet Biosciences Inc. | $973,037 | 0.5% | NEW | — |
New Positions (3)
Exited Positions (12)
$VOR Vor Biopharma Inc.
$VRDN Viridian Therapeutics, Inc.\DE
$OCS Oculis Holding AG
$TRVI Trevi Therapeutics, Inc.
$CHRS Coherus Oncology, Inc.
$KLRS Kalaris Therapeutics, Inc.
$QURE uniQure N.V.
$NUVB Nuvation Bio Inc.
$EVMN Evommune, Inc.
$ALDX Aldeyra Therapeutics, Inc.
$CNTB Connect Biopharma Holdings Ltd
$MSLE Satellos Bioscience Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Propel Bio Management, LLC including:
Track Propel Bio Management, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Propel Bio Management, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Propel Bio Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Propel Bio Management, LLC (SEC CIK: 1969764), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Propel Bio Management, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.